Psychiatry and Neurology, Neurology · Saint Louis, MO
NPI
1689194730
Since 2017
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4921 Parkview Pl, Div Neurology Multiple Sclerosis, 7th Fl
Saint Louis, MO, 63110
Phone (314) 362-3293
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,021
120 services
Medicare patients, 2024
39
Average age 63
Drug cost, 2024
$1.2M
340 prescriptions
Company payments, 2025
$27K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew R Brier was code 99232 (hospital e&m - subsequent), 44 times for 11 patients. In total Matthew R Brier billed 120 services in 11 codes, and Medicare paid $8,021.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 44 | 11 | $59.79 | $2,631 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 26 | 24 | $12.61 | $328 |
| 99215 Office E&M - Established | Office | 21 | 17 | $117.69 | $2,471 |
By year: 2022 $6,753 for 71 services; 2023 $9,577 for 114 services; 2024 $8,021 for 120 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew R Brier prescribed most often to Medicare patients was Gabapentin, with 55 prescriptions and refills. In total Matthew R Brier wrote 340 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 55 | 88 | 12 | $1,818 |
| Duloxetine Hcl Generic | 28 | 52 | Under 11 | $439 |
| Kesimpta Pen Ofatumumab | 27 | 27 | Under 11 | $237K |
| Baclofen Generic | 25 | 41 | Under 11 | $837 |
| Enspryng Satralizumab-Mwge | 25 | 32 | Under 11 | $595K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 23 | 23 | Under 11 | $250 |
| Bupropion Xl Bupropion Hcl | 16 | 24 | Under 11 | $75.02 |
| Dalfampridine Er Dalfampridine | 15 | 15 | Under 11 | $16K |
| Fingolimod Fingolimod Hcl | 13 | 13 | Under 11 | $8,100 |
| Copaxone Glatiramer Acetate | 12 | 12 | Under 11 | $84K |
| Ampyra Dalfampridine | 12 | 12 | Under 11 | $49K |
Brand drugs: 99 claims; generic drugs: 241 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew R Brier $27K ($27K in general payments such as food, travel and fees) from 8 companies. The largest payer was Genzyme Corporation with $12K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.